GI Signals · Trends

The digest, over time.

Charts from the 11 published issues so far: how selective it stays, which areas are busy, and what moves the standard of care.

01 / OVER TIME

How selective it stays

Papers surfaced as a share of papers screened, each week (oldest first). It should stay low and steady.

0%10%20%30%40%Surfaced %7%06/24/269%16%07/19/2637%31%08/02/2634%28%08/16/2629%33%08/30/2633%31%09/13/26
02 / OVER TIME

Which areas are busy

Surfaced papers by subspecialty, week by week (oldest at left). A busy section or a quiet stretch shows up week to week.

06/24/26
07/12/26
07/19/26
07/26/26
08/02/26
08/09/26
08/16/26
08/23/26
08/30/26
09/06/26
09/13/26
IBD
5
1
5
6
19
9
5
11
6
24
9
Hepatology
2
5
4
12
36
14
9
6
15
30
16
Esophagus/Reflux
2
2
2
4
5
1
6
5
3
Pancreas/Biliary
3
2
5
2
11
5
3
6
5
10
3
Endoscopy
5
5
4
21
18
16
8
8
13
15
10
Motility
4
5
7
9
3
3
5
2
6
1
Colorectal
5
2
1
3
9
5
2
3
9
1
Nutrition
3
2
3
2
3
2
2
03 / OVER TIME

How much each week shifts the standard

Mean standard-shift by week, oldest first (1 reinforces current practice, 5 challenges it). A busy week reads differently from a quiet one.

12345Mean shift3.306/24/262.12.607/19/261.91.508/02/262.12.108/16/262.31.508/30/261.62.509/13/26
04 / OVER TIME

Which journals show up most

Cumulative surfaced papers by journal: the journals that carry the signal, week after week.

Inflamm Bowel Dis48
Dig Dis Sci34
Liver International33
Clin Gastro Hep32
Gut29
J Gastro Hep26
GIE26
Aliment Pharm Ther25
05 / OVER TIME

The run so far

One tile per week (oldest first): how many papers surfaced and the spread of their signal scores.

06/24/26 · #1
29surfaced
score 7 to 92
07/12/26 · #2
17surfaced
score 32 to 80
07/19/26 · #3
28surfaced
score 37 to 83
07/26/26 · #4
58surfaced
score 32 to 80
08/02/26 · #5
107surfaced
score 35 to 87
08/09/26 · #6
52surfaced
score 32 to 79
08/16/26 · #7
28surfaced
score 16 to 79
08/23/26 · #8
41surfaced
score 40 to 88
08/30/26 · #9
53surfaced
score 38 to 95
09/06/26 · #10
101surfaced
score 36 to 89
09/13/26 · #11
45surfaced
score 37 to 92
06 / THIS ISSUE

The signal map

Every surfaced paper placed by study rigor and novelty; dot size is journal standing. Top right is the week's must-read.

EmergingReinforcesRefinesChangesstrong evidence · moves the standardnarrative reviewguideline →How far it moves the standardEvidence strength
07 / THIS ISSUE

What drove each score

The top papers, each split into the four scoring parts, so you can see why a paper ranked without opening its card.

Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial.92
International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update.79
HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER).77
Personalised prediction of the individual risk of liver-related events in MASLD using the dynamics of non-invasive tests.75
Clinical Spectrum of Esophageal Motility Disorders in Nonobstructive Dysphagia: A Multicenter, Multiethnic Study.72
A prospective clinical trial of eus-shear wave measurement of liver and spleen for hepatic fibrosis.44
Assessing Strategies to Mitigate the Effect of Age When Using FIB-4 Index to Screen for MASLD-Related Liver Fibrosis.69
AGA Clinical Practice Update on Management of Ampullary Neoplasms: Expert Review.62
Topical Vitamin C and N-Acetylcysteine for Reducing Symptoms After Lugol Chromoendoscopy: A Multicenter Randomized Controlled Trial.43
Pharmacokinetic Predictor of Infection in Patients With Inflammatory Bowel Disease Treated With Intravenous and Subcutaneous Infliximab.61
Influence of socioeconomic development on incidence and disease phenotype in inflammatory bowel disease: a population-based incident study across 16 regions.61
Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).65
Study rigorShiftPractice relevanceJournal standing